IMMUNE-RELATED ADVERSE EVENTS AND THEIR MANAGEMENT IN CANCER PATIENTS AGED 75 YEARS AND OLDER RECEIVING IMMUNOTHERAPY
Objective: Immune checkpoint inhibitors (ICIs) have improved cancer treatment outcomes but may cause immune-related adverse events (irAEs). Data regarding immunotherapy safety in elderly patients remain limited. This study aimed to evaluate irAE distribution, severity, and associated clinical factors in cancer patients...